QCG
CLYM

Quadrant Capital Group’s Climb Bio CLYM Stock Holding History

Quadrant Capital Group’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-488
Closed -$2.48K – 2807
2024
Q3 		$2.48K Buy
+488
New +$3.45K ﹤0.01% 2459

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrant Capital Group's CLYM Position: Q4 2024 in Review

Quadrant Capital Group sold out of Climb Bio (CLYM) in Q4 2024, closing a stake of 488 shares — an estimated $2.48K sold.

Quadrant Capital Group first reported a position in CLYM in Q3 2024 and held it in 1 quarter. The position peaked at $2.48K in Q3 2024. 80 funds tracked by Wall St. Rank hold CLYM as of Q4 2024.

  • Quadrant Capital Group reported no remaining Climb Bio position as of Q4 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 488 Climb Bio shares in Q4 2024, an estimated $2.48K.
  • Quadrant Capital Group first reported a position in Climb Bio in Q3 2024 and held it in 1 quarter.
  • Quadrant Capital Group's Climb Bio position peaked at $2.48K in Q3 2024.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q4 2024.

Based on Quadrant Capital Group's 13F filing for Q4 2024, filed 13 Feb 2025.